Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But take it from GSK vaccines chief Moncef Slaoui--splitting apart is a bad idea, at least on the vaccines front.
For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>
Being an R&D chief at a major biopharma company in today's environment of major research cutbacks, patent expirations and pressure from investors to speed new drugs to market is no easy...
It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.
GlaxoSmithKline and Johnson & Johnson are teaming up with Index Ventures to launch a $200 million fund devoted exclusively to backing early-stage biotechs
Amid GlaxoSmithKline's ($GSK) major push to expand in China, the London-based drugmaker has located a new R&D unit in that country that will investigate traditional Chinese medicines. The move is
Now that GlaxoSmithKline ($GSK) has hit the three-year mark on its closely watched experiment with Drug Performance Units, R&D Chairman Moncef Slaoui (pictured) tells FierceBiotech the pharma
Following a three-year review of its new approach to R&D, GlaxoSmithKline ($GSK) today revealed that it has decided to ax three of its 38 tightly-focused research units and add four more in a
In one of the most anticipated R&D events of the year, GlaxoSmithKline ($GSK) execs are readying a summary judgment on the results of the first three-year round of results for their
Of all the Big Pharmas anxiously attempting to reinvent the way they discover and develop new drugs, few if any have been as ambitious about creating a new R&D culture as GlaxoSmithKline ($GSK).